🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BostonGene contributed to a white paper with Friends of Cancer Research entitled “Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications.” The paper highlights key considerations and strategic recommendations to improve the

AI will not replace pathologists, but it can help supplement their work for a more accurate diagnostic result - Joe Lennerz from BostonGeneCorp #FriendsDx

As AI evolves in healthcare, regulatory science has to guide responsible adoption. #FriendsDx explored how oversight shapes #AI, digital pathology, & CDx for rare biomarkers, ensuring innovation expands access while ensuring patient safety. Read the recap: bit.ly/3CDaf9W

We are excited to announce a collaboration with BeiGeneGlobal to advance biomarker discovery in mantle cell lymphoma. This collaboration will leverage BostonGene's comprehensive AI platform and molecular profiling to identify biomarkers associated with disease response and

BostonGene wins “Cancer Immunology Solution of the Year” from BioTech Breakthrough for our AI-driven, blood-based immune system profiling platform! Read more: bostongene.com/news-and-publi…

We are proud to be named a Fierce Life Sciences Innovation Awards Winner in the AI Innovation category for our AI-driven Digital Pathology Platform. This award highlights our platform’s ability to enhance accuracy, streamline analysis and reduce variability across diverse data

Meet BostonGene at #AACR25 Discover our latest AI-driven innovations transforming cancer care. Learn how we leverage multiomics and advanced AI solutions to deliver personalized treatment insights and accelerate the development of life-saving therapies. Email

BostonGene is proud to announce a partnership with Johnson & Johnson to evaluate biomarkers for colorectal cancer and multiple myeloma using AI-driven molecular profiling in clinical trials—a strategic collaboration aimed at accelerating drug discovery and development in

We are pleased to announce the appointment of Ferran Prat, PhD, JD, as Chief Commercial Officer. In this role, Dr. Prat will oversee BostonGene’s commercial strategy, including sales, marketing and business development. "I am excited to help lead this next chapter of growth as

We're just over two weeks away from #AACR25! Join us to explore our latest AI-powered innovations that are transforming cancer care. Discover how BostonGene harnesses multiomics and advanced AI to deliver personalized treatment insights and accelerate the development of

BostonGene will present four abstracts at #AACR25, highlighting the power of our AI-enabled, integrated multiomic platform to drive precision oncology. Additionally, Ferran Prat, PhD, JD, BostonGene’s Chief Commercial Officer, will speak at the AACR educational session titled

Attend our poster presentations at #AACR25! We’ll present new research demonstrating the power of our AI-enabled, multiomic platform to drive precision oncology. By combining comprehensive genomic, transcriptomic, and immune profiling, our platform enables high-resolution tumor

It’s almost go time!!! Putting on the finishing touches! Stop by booth #2452! #AACR25

Join us at the 2025 ASCO® Annual Meeting on May 31 – June 2 in Chicago! To schedule a meeting or learn more, email us at [email protected]! #ASCO25

Meet with us at #ASCO25! BostonGene will showcase how our multimodal AI platform is accelerating oncology drug development—from biomarker discovery to patient stratification and smarter trial design. Email [email protected] to schedule a meeting during #ASCO25!

We’re proud to join Mediaplanet USA on their Future of Cancer Care campaign in USA TODAY. From precision medicine to patient empowerment, this campaign highlights the breakthroughs shaping tomorrow’s oncology. Learn more: bit.ly/3STi9jN #FutureOfCancerCare #Oncology

It’s go time!! #ASCO25 Stop by booth #15147 to learn how BostonGene’s multimodal AI platform is accelerating oncology drug development—from biomarker discovery and patient stratification to smarter, more efficient trial design. Learn more: bostongene.com/news-and-publi…